AR and metastatic prostate carcinoma: This aptamer was then tested on cells that were androgen receptor (AR)-negative (PC3) and AR-positive (LNCaP and 22Rv1), because ARs may suppress metastatic potential and are often upregulated in patients with metastatic prostate cancer [121,122].